• Philips wins patent case against Nintendo in UK Friday, 20 Jun 2014 | 9:24 AM ET

    Philips Electronics said on Friday it had won a patent infringement cases against Nintendo in the United Kingdom.

  • SCOTUS raises bar on what software can be patented Thursday, 19 Jun 2014 | 2:37 PM ET

    The Supreme Court unanimously upheld the patentability of software Thursday, but raised the bar on what types of software are protected.

  • Sneaker war! Skechers slaps Reebok with patent suit Thursday, 19 Jun 2014 | 11:29 AM ET

    Sport shoes maker Skechers said it filed a lawsuit against Reebok, alleging infringement of patents related to the company's Go Walk shoes.

  • IBM, Pure Storage sign cross-licensing agreement Thursday, 19 Jun 2014 | 10:31 AM ET
    Pure Storage FlashArray.

    IBM and Pure Storage announced in a release that the private computer storage company has acquired more than 100 technology patents from IBM.

  • Washington Redskins trademarks cancelled  Wednesday, 18 Jun 2014 | 10:19 AM ET

    The U.S. Patent and Trademark Office has cancelled the Washington Redskins' trademark registration saying the name is "disparaging" to Native Americans.

  • Tesla opens patents: What's Musk's end game?  Thursday, 12 Jun 2014 | 3:24 PM ET

    Tesla CEO Elon Musk has announced it is opening up all its patents to competitors to spur innovation. CNBC's Phil LeBeau has the details.

  • Elon Musk opens Tesla's patents  Thursday, 12 Jun 2014 | 1:05 PM ET

    CNBC's Phil LeBeau reports Tesla CEO Elon Musk has announced the automaker will open up its patents to spur innovation in the auto industry.

  • Patent system not broken: Inventergy CEO  Tuesday, 10 Jun 2014 | 8:40 AM ET

    Patents help spur innovation and competitiveness in the U.S., says Joe Beyers, Inventergy chairman and CEO.

  • Business of IP patents  Tuesday, 10 Jun 2014 | 8:37 AM ET

    Joe Beyers, Inventergy chairman and CEO, shares the company's business model and reasons for going public.

  • Why Merck's Idenix deal is bad news for Gilead Monday, 9 Jun 2014 | 2:34 PM ET

    Analysts say there's more to Merck's interest in Idenix than its drug portfolio: intellectual property. And that's why Gilead's shares are lower.

  • Revolution coming to biology: CEO  Friday, 6 Jun 2014 | 11:33 AM ET

    "What happened in electronics and software is about to happen in biology," says Jay Walker, Patent Properties chairman, discussing the impending explosion in the health and wellness sector. Walker also explains how Apple's "HealthKit" may be paving the way towards a market with tech driven, individualized health care.

  • Over-the-counter Cialis?  Wednesday, 28 May 2014 | 2:16 PM ET

    CNBC's Meg Tirrell reports Sanofi and Eli Lilly announced an agreement to pursue regulatory approval of an over-the-counter version of erectile dysfunction drug Cialis.

  • How not to fear biotech  Thursday, 15 May 2014 | 1:24 PM ET

    Discussing hot picks in the biotech space, with Matthew Roden, UBS executive director.

  • Apple vs. Samsung: Who wins?  Tuesday, 6 May 2014 | 1:41 PM ET

    The epic patent fight between Samsung and Apple ended on Monday after a jury ordered Samsung pay $120 million in damages for copying iPhone technology. Kurt Eichenwald, Vanity Fair, profiled the mobile giants in the June issue.

  • Priceline founder: Lessons of Apple-Samsung fight Monday, 5 May 2014 | 2:17 PM ET

    The Samsung-Apple litigation underscored the troubled U.S. patent system, and something worse, Priceline.com founder Jay Walker tells CNBC.

  • US licensing system totally broken: Jay Walker  Monday, 5 May 2014 | 10:33 AM ET

    Priceline.com founder Jay Walker, discusses the patent war between Apple and Samsung and explains his new venture created to solve America's patent problem.

  • Build your own portfolio with these trends  Thursday, 1 May 2014 | 12:58 PM ET

    Hardeep Walia, co-founder and CEO of Motif Investing, shares his firm's findings on the most popular trends in investing right now, including high-yield dividends.

  • Why Apple's the underdog in this Samsung trial Thursday, 10 Apr 2014 | 3:23 PM ET

    Apple is making some broad claims about what it owns and will have to make a strong case to prove it actually deserves as much as it is asking for.

  • CNBC's Jim Cramer speaks with Robert Hugin, Celgene chairman & CEO, about America's need to build a stronger and more sustainable ecosystem of innovation to continue as the world leader in biomedical innovation.

  • Alkermes is a true drug innovator: CEO  Thursday, 10 Apr 2014 | 8:21 AM ET

    Richard Pops, chairman & CEO of Alkermes, discusses Alkermes' new injectable drug for the treatment of schizophrenia. We have more psychiatry products in our pipeline, reveals Pops.